Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck

Article

Abstract: The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, ele

Palabras claves:

Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, nimotuzumab, Squamous cell carcinoma of the head and neck, Targeted therapy

Autores:

Alert J., Bahi R.D.C., Bárbara Wilkinson, Bilbao M.A., Carmen Elena Viada, De Armas E.L., Frómeta M., Galainena J.J., Gracias E., Iznaga N., Leonard I., Luaces P.L.o., Muchuli C.R., Mulén B., Mullens V., Pérez K., Pineda I., Rivero T.C., Rodríguez E., Rodríguez M.O., Tania Crombet, Torres O., Vinageras E.N.

Fuentes:

scopus